Intrommune
New York City, US · 2 known investors
Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
Founders & leadership
Investors · 2
Competitors · 7
by search overlap
Inimmune8 shared keywordsInimmune is a clinical-stage biotech company developing immunotherapies for allergy, cancer, infectious, and autoimmune diseases. The company combines immunology and vaccine expertise to advance its clinical and pre-clinical pipeline.
NexImmune8 shared keywordsNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).
Evommune8 shared keywordsEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.
Primmune Therapeutics7 shared keywordsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Avammune6 shared keywordsAvammune is a biotech company developing novel therapeutic modalities to address hard-to-treat cancers with distinct mechanisms of action. The company focuses on patient-centric oncology drug discovery, emphasizing improved compliance, ease of administration, and greater accessibility.
Inmune Bio6 shared keywordsINmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Immunome6 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
Companies competing with Intrommune for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Intrommune do?
- Intrommune is a biotechnology company developing oral mucosal immunotherapy (OMIT), which delivers allergenic proteins through a specially formulated toothpaste to treat peanut and other food allergies. Its products target patients and families managing food allergies, spanning early allergen introduction in at-risk children and treatment options for those living with food allergy.
- Who are Intrommune's investors?
- Intrommune's investors include Red Bear Angels, Robin Hood Ventures.
- Where is Intrommune headquartered?
- Intrommune is headquartered in New York City, US.